AAV Gene Therapy Successfully Protects Against Ebola in Mice
Infectious disease researchers have discovered a new method for
effectively protecting against and treating Ebola infections. The study,
performed in mice, used an adeno-associated virus (AAV) to deliver
monoclonal antibody genes against Ebola. Similar viral vector treatments
have been used to effectively treat human immunodeficiency virus (HIV)
infections.
“Our goal is to make an antibody-based therapy that can protect against all strains of Ebola, and potentially Marburg virus, as well,” says Prof., who, along with PhD student found a new way to fight Ebola. “It would be used to stop the spread of the virus in outbreak situations.”
Traditional monoclonal antibody (mAb) treatments for Ebola are promising but are limited by the resources required for production and the immunity they provide is short-term. Using a viral vector method, anti-Ebola monoclonal antibody genes are delivered to the cell and the cell will produce the antibody and secrete it into the bloodstream to fight an infection. The research team demonstrated that in mice, 100 percent protection was provided against an Ebola infection with a mixture of two different types of antibodies and 83 percent protection was provided with a different antibody cocktail. The gene therapy was shown to provide protection from the disease for five months following administration.
“We are hoping to use this technology in a post-exposure scenario. Let’s say someone has been exposed to Ebola. The idea would be to give them this AAV vector to start producing the antibodies that prevent death, commented the Prof.”
The preliminary findings are promising and the team is moving forward to develop a gene-based therapeutic or vaccine to Ebola or one that can be used to treat other filovirus infections such as Marbug.
THIS IS ONLY FOR INFORMATION, ALWAYS CONSULT YOU PHYSICIAN BEFORE HAVING ANY PARTICULAR FOOD/ MEDICATION/EXERCISE/OTHER REMEDIES.
“Our goal is to make an antibody-based therapy that can protect against all strains of Ebola, and potentially Marburg virus, as well,” says Prof., who, along with PhD student found a new way to fight Ebola. “It would be used to stop the spread of the virus in outbreak situations.”
Traditional monoclonal antibody (mAb) treatments for Ebola are promising but are limited by the resources required for production and the immunity they provide is short-term. Using a viral vector method, anti-Ebola monoclonal antibody genes are delivered to the cell and the cell will produce the antibody and secrete it into the bloodstream to fight an infection. The research team demonstrated that in mice, 100 percent protection was provided against an Ebola infection with a mixture of two different types of antibodies and 83 percent protection was provided with a different antibody cocktail. The gene therapy was shown to provide protection from the disease for five months following administration.
“We are hoping to use this technology in a post-exposure scenario. Let’s say someone has been exposed to Ebola. The idea would be to give them this AAV vector to start producing the antibodies that prevent death, commented the Prof.”
The preliminary findings are promising and the team is moving forward to develop a gene-based therapeutic or vaccine to Ebola or one that can be used to treat other filovirus infections such as Marbug.
THIS IS ONLY FOR INFORMATION, ALWAYS CONSULT YOU PHYSICIAN BEFORE HAVING ANY PARTICULAR FOOD/ MEDICATION/EXERCISE/OTHER REMEDIES.
PS- THOSE INTERESTED IN RECIPES ARE FREE TO VIEW MY BLOG-
HTTP:GSEASYRECIPES.BLOGSPOT.COM/
HTTP:GSEASYRECIPES.BLOGSPOT.COM/
FOR INFO ABOUT KNEE REPLACEMENT, YOU CAN VIEW MY BLOG-
HTTP://KNEE REPLACEMENT-STICK CLUB.BLOGSPOT.COM/
FOR CROCHET DESIGNS
HTTP://MY CROCHET CREATIONS.BLOGSPOT.COM
FOR CROCHET DESIGNS
HTTP://MY CROCHET CREATIONS.BLOGSPOT.COM
Labels: adeno-associated virus(AAV), Ebola, HIV, human, immunodeficient, infectious diseases, monoclonal antibody(mAb), new method, protect against, vector
posted by G S Iyer at 9:23 AM
0 Comments:
Post a Comment
<< Home